Cardiovascular disease (CVD) is the leading cause of death in Western societies, affecting both young and old patients. Currently there are no cures for these conditions and this is unacceptable to us. Research at the CardioVascular Center (CVC) ranges from experimental to clinical studies, evaluating behavioural, pharmaceutical, and device therapies with the aim to ultimately find a cure for CVD.

At the CVC creative ideas and our cutting edge technology shape the treatments of tomorrow. Our research is dedicated to preserve cardiac function over time and ranges from basic and translational science to multicenter clinical trials. We investigate the mechanisms that drive CVD, translate these findings into new treatments, and develop patient-tailored therapies. Our research focuses on:

  • heart failure
  • atrial fibrillation
  • experimental cardiology
  • ischemic heart disease

Please also visit: https://www.groningencardiology.com/.

Video bekijken Scannen
Relevance

We are dedicated to fight CVD in the ageing population

CVD is the leading cause of morbidity and mortality, with ageing being a primary risk factor. With the ageing of our population, the prevalence of CVD will only increase. This is particularly relevant for the Northern Netherlands, a region with a high incidence of risk factors and unfavorable socioeconomic circumstances.

Research grounded in care and society

Our investigators and doctors are well-embedded in societal organizations ensuring timely dissemination into clinical care and society. Our studies span from experimental to clinical research, interventions, and cohort studies.

We run intervention studies including pharmacological interventions, lifestyle interventions, and device interventions. Besides, we do cohort studies to identify prognostic factors in the general population and populations at high risk for CVD. We also investigate the role of co-morbidities such as renal disease, cancer, obesity and diabetes.

We contribute to a reduction in deaths due to CVD

Our translational approach and high quality research has contributed to a reduction in deaths due to CVD, thereby contributing to healthy ageing.

  • We combine our regional approach with numerous international collaborations, which have generated results for patients, policy makers, and other stakeholders.

    • Our investigators have been members of guideline committees, leading national and international committees, and innovative clinical trials. The Cardiology Department is regarded as an international referral center for atrial fibrillation and heart failure treatment. As such, our work has direct and major impact for science, treatment guidelines, patients, and policy makers.

    • We contributed to nearly all therapies for new atrial fibrillation and heart disease that were developed in the last decade.

    • We started a regional referral system for patients with CVD, enforcing the implementation of our new findings in the entire Northern region of the Netherlands (“HartNet”).

    • In our research networks, we have established connections with patients and patient committees that now are valuable partners in the design and execution of clinical studies.

  • G-CURE aims to become a global scientific leader and service provider in the development of new (pharmacological) treatments for cardiovascular diseases with a focus on heart failure, ischemic heart disease and atrial fibrillation. Born within the Cardiology department of one of the most advanced university hospitals in Europe, G-CURE is a modern institute built on strong scientific foundations dating back to the 18th century.  We offer our unique skill sets and combined expertise to pharmaceutical, biotech and related industries, with services ranging from experimental animal studies, clinical trials, data analysis and consultancy. We offer the full continuum from studying pathophysiology yielding novel mechanistic targets, to pre-clinical and phase I, II and III drug development studies.